-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagene Doses First Patient in Phase 1 Trial of ADG138 for HER2-Positive Solid Tumors

PUBT·11/19/2026 12:05:36
Listen to the news
Adagene Doses First Patient in Phase 1 Trial of ADG138 for HER2-Positive Solid Tumors
  • Adagene dosed the first patient in a Phase 1 trial of ADG138, a double-masked T-cell engager for HER2-positive advanced solid tumors.
  • The trial will assess safety and preliminary efficacy in heavily pretreated patients, establishing a recommended Phase 2 dose.
  • Reported preclinical results showed preserved antitumor activity, including in Enhertu-resistant models, with reduced cytokine release compared with an unmasked T-cell engager.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-129932), on November 19, 2026, and is solely responsible for the information contained therein.